Nitroethane

Nitroethane

SCHEMBL49993

CC[N+](=O)[O-].ClC(Cl)(Cl)Cl

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.73
ALDH1A1 P00352 6/20 0.47
TDP1 Q9NUW8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitroethane SCHEMBL35035 0.86
Nitroethane SCHEMBL1332217 0.86
Nitroethane SCHEMBL11203503 0.83
Nitroethane SCHEMBL11366611 0.83
Nitroethane SCHEMBL7774447 0.82
Nitroethane SCHEMBL27939198 0.82
Nitroethane SCHEMBL29866506 0.82
Nitroethane SCHEMBL27781345 0.82
Nitroethane SCHEMBL27907184 0.80
Nitroethane SCHEMBL1011599 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752133-A1 SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID Esperion Therapeutics, Inc. (US) 2020-12-23 EP disclosed
WO-2019161307-A1 SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID ESPERION THERAPEUTICS, INC. (US) 2019-08-22 WO disclosed
CN-108354930-A Include the pharmaceutical preparation of 1- (β-D- glucopyranosyls) -2- thienyl-methyl benzene derivatives 詹森药业有限公司 2018-08-03 CN disclosed
CN-106983744-A Conjoint therapy for treating diabetes 詹森药业有限公司 2017-07-28 CN disclosed
US-9393192-B2 Methods and dosage forms for controlled delivery of paliperidone and risperidone ALZA CORPORATION 2016-07-19 US disclosed
CN-103800300-A Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms ALZA CORP 2014-05-21 CN disclosed
US-20140044782-A1 CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS ALZA CORPORATION (US) 2014-02-13 US disclosed
CN-1957909-B Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms ALZA CORP 2013-09-11 CN disclosed
US-20130209525-A1 CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS ALZA CORPORATION (US) 2013-08-15 US disclosed
EP-1951232-B1 METHODS OF REDUCING ALCOHOL-INDUCED DOSE DUMPING FOR OPIOID SUSTAINED RELEASE ORAL DOSAGE FORMS ALZA CORP (US) 2013-04-03 EP disclosed
EP-1126853-A1 CONTROLLED DELIVERY OF ANTIDEPRESSANTS ALZA CORPORATION (US) 2001-08-29 EP disclosed
EP-1126827-A2 CONTROLLED DELIVERY OF ACTIVE AGENTS ALZA CORPORATION (US) 2001-08-29 EP disclosed
WO-2001019337-A2 DOSAGE FORMS AND METHODS FOR PROVIDING EFFECTIVE REBOXETINE THERAPY WITH ONCE-A-DAY DOSING ALZA CORPORATION (US) 2001-03-22 WO disclosed
US-6096339-A Dosage form, process of making and using same ALZA CORPORATION (US) 2000-08-01 US disclosed
WO-2000038655-A1 DOSAGE FORMS COMPRISING POROUS PARTICLES ALZA CORPORATION (US) 2000-07-06 WO disclosed
WO-2000025753-A2 CONTROLLED DELIVERY OF ACTIVE AGENTS ALZA CORPORATION (US) 2000-05-11 WO disclosed
WO-2000025790-A1 CONTROLLED DELIVERY OF ANTIDEPRESSANTS ALZA CORPORATION (US) 2000-05-11 WO disclosed
EP-0907358-A2 UNIFORM DRUG DELIVERY THERAPY ALZA CORPORATION (US) 1999-04-14 EP disclosed
WO-1997037640-A2 UNIFORM DRUG DELIVERY THERAPY ALZA CORPORATION (US) 1997-10-16 WO disclosed
US-5413572-A Osmotic dosage system for liquid drug delivery ALZA CORPORATION (US) 1995-05-09 US disclosed